New research by drug industry contractor IQVIA questions whether claims identifiers can be used successfully to exclude 340B-purchased drugs from new Medicare drug inflation rebates or to protect manufacturers from paying both a new negotiated Medicare price and a 340B price on the same drug.
“340B modifiers provide visibility to 340B transactions in some segments of payers, pharmacies, and products but not others,” IQVIA said in the Feb. 21 white paper. “Further thought needs to be given to determine the optimal methods for consistently identifying 340B drugs in order to support implementation of non-duplication and inflationary rebate provisions” of last year’s Inflation Reduction Act.
New research by drug industry contractor IQVIA questions whether claims identifiers can be used successfully to exclude 340B-purchased drugs from new Medicare drug inflation rebates or to protect manufacturers from paying both a new negotiated Medicare price and a 340B price on the same drug.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
